Q4 & FY22 Highlights

Key Performance Highlights • • . Q4 FY22 & FY22: Revenues up by 12.7% Y-o-Y to Rs. 485.5 crore in Q4 FY22. Revenue up by 32% to Rs 2087.4 crore in FY22 Normalised EBITDA* is Rs. 130.7 crore, margin of 26.9% in Q4 FY22. In FY22, Normalised EBITDA* is Rs 600.4 crore, margin at 28.8%. Normalised Profit After Tax** at Rs. 72.9 crore, margin of 15.0% in Q4 FY22, Normalised PAT** in FY22 is at Rs 369.1 crore, margin of 17.7% Net Cash and Cash Equivalents at Rs. 344 crore as on March 31, 2022 Witnessed strong trajectory in non-COVID business following ease of mobility restrictions across the country; growth in non-COVID business at 12.2% Y-o-Y Revenues from Non-COVID business at Rs 419.7 Cr with 'Swasthfit' contributing 18% Enhanced focus on driving volumes while maintaining prices; tactical penetration in West & South through modular cluster city approach playing out well. HUB lab program helping add revenue gains *Normalised EBITDA excl. RSU, CSR **Normalised PAT excl. notional depreciation on consolidation of Suburban Note: Results includes Suburban Diagnostics 28 Dr Lal PathLabs

View entire presentation